IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v19y2022i12p7281-d838392.html
   My bibliography  Save this article

Using the Dynamic SWOT Analysis to Assess Options for Implementing the HB-HTA Model

Author

Listed:
  • Barbara Więckowska

    (Department of Social Insurance, Warsaw School of Economics, 02-554 Warszawa, Poland)

  • Monika Raulinajtys-Grzybek

    (Department of Management Accounting, Warsaw School of Economics, 02-554 Warszawa, Poland)

  • Katarzyna Byszek

    (Department of Social Insurance, Warsaw School of Economics, 02-554 Warszawa, Poland)

Abstract

This paper is aimed at exploring the role of the HB-HTA ecosystem as an important pathway for popularizing the implementation of innovations in healthcare organizations. The scientific debate has largely been focused on the rising importance of HB-HTA and the principles guiding the process. Solutions implemented by individual countries differ, which may be rooted in historical, cultural, and institutional differences. Our understanding of the impact of individual countries’ healthcare systems on HB-HTA solutions and infrastructure still lacks a basis in interpretative studies. A conceptual framework is proposed to assess the aptness of the HB-HTA model designed for hospitals operating in a country or region, focused on the concepts of adaptiveness and responsiveness to features of the healthcare system present there. A tool is proposed for investigating factors that are likely to assist the successful implementation of the HB-HTA ecosystem. A dynamic SWOT analysis on the case of the HB-HTA model designed for Poland provides interesting insights into the building of the conceptual framework. The results of this study help explain how to create an HB-HTA model that is best adapted to the regional or national healthcare system, including potential risks and opportunities.

Suggested Citation

  • Barbara Więckowska & Monika Raulinajtys-Grzybek & Katarzyna Byszek, 2022. "Using the Dynamic SWOT Analysis to Assess Options for Implementing the HB-HTA Model," IJERPH, MDPI, vol. 19(12), pages 1-17, June.
    • Handle: RePEc:gam:jijerp:v:19:y:2022:i:12:p:7281-:d:838392
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/19/12/7281/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/19/12/7281/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Julia Simões Corrêa Galendi & Carlos Antonio Caramori & Clarissa Lemmen & Dirk Müller & Stephanie Stock, 2021. "Expectations for the Development of Health Technology Assessment in Brazil," IJERPH, MDPI, vol. 18(22), pages 1-12, November.
    2. László Gulácsi & Alexandru Rotar & Maciej Niewada & Olga Löblová & Fanni Rencz & Guenka Petrova & Imre Boncz & Niek Klazinga, 2014. "Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 13-25, May.
    3. Kisser, Agnes & Tüchler, Heinz & Erdös, Judit & Wild, Claudia, 2016. "Factors influencing coverage decisions on medical devices: A retrospective analysis of 78 medical device appraisals for the Austrian hospital benefit catalogue 2008–2015," Health Policy, Elsevier, vol. 120(8), pages 903-912.
    4. Aris Angelis & Ansgar Lange & Panos Kanavos, 2018. "Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(1), pages 123-152, January.
    5. Carmelina Bevilacqua & Ilaria Giada Anversa & Gianmarco Cantafio & Pasquale Pizzimenti, 2019. "Local Clusters as “Building Blocks” for Smart Specialization Strategies: A Dynamic SWOT Analysis Application in the Case of San Diego (US)," Sustainability, MDPI, vol. 11(19), pages 1-25, October.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Maciej Furman & Małgorzata Gałązka-Sobotka & Damian Marciniak & Iwona Kowalska-Bobko, 2022. "Possibilities of Implementing Hospital-Based Health Technology Assessment (HB-HTA) at the Level of Voivodeship Offices in Poland," IJERPH, MDPI, vol. 19(18), pages 1-15, September.
    2. Diego Augusto Santos Silva & Carolina Fernandes da Silva, 2022. "Physical Activity Policies for Children and Adolescents in Brazil: Analysis for the Report Card Brazil on Physical Activity for Children and Adolescents," IJERPH, MDPI, vol. 19(16), pages 1-11, August.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Wettstein, Dominik J. & Boes, Stefan, 2022. "How value-based policy interventions influence price negotiations for new medicines: An experimental approach and initial evidence," Health Policy, Elsevier, vol. 126(2), pages 112-121.
    2. Kanavos, Panos & Visintin, Erica & Gentilini, Arianna, 2023. "Algorithms and heuristics of health technology assessments: A retrospective analysis of factors associated with HTA outcomes for new drugs across seven OECD countries," Social Science & Medicine, Elsevier, vol. 331(C).
    3. László Gulácsi & Fanni Rencz & Márta Péntek & Valentin Brodszky & Ruth Lopert & Noémi Hevér & Petra Baji, 2014. "Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 27-34, May.
    4. László Gulácsi, 2014. "Biological and biosimilar therapies in inflammatory conditions: challenges for the Central and Eastern European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 1-4, May.
    5. Kleinhout-Vliek, Tineke & de Bont, Antoinette & Boer, Bert, 2017. "The bare necessities? A realist review of necessity argumentations used in health care coverage decisions," Health Policy, Elsevier, vol. 121(7), pages 731-744.
    6. Riswandy Wasir & Sylvi Irawati & Amr Makady & Maarten Postma & Wim Goettsch & Erik Buskens & Talitha Feenstra, 2019. "Use of medicine pricing and reimbursement policies for universal health coverage in Indonesia," PLOS ONE, Public Library of Science, vol. 14(2), pages 1-19, February.
    7. Mónica D. Oliveira & Inês Mataloto & Panos Kanavos, 2019. "Multi-criteria decision analysis for health technology assessment: addressing methodological challenges to improve the state of the art," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(6), pages 891-918, August.
    8. Rotar, Alexandru M. & Preda, Alin & Löblová, Olga & Benkovic, Vanesa & Zawodnik, Szymon & Gulacsi, Laszlo & Niewada, Maciej & Boncz, Imre & Petrova, Guenka & Dimitrova, Maria & Klazinga, Niek, 2018. "Rationalizing the introduction and use of pharmaceutical products: The role of managed entry agreements in Central and Eastern European countries," Health Policy, Elsevier, vol. 122(3), pages 230-236.
    9. Steve J. Bickley & Alison Macintyre & Benno Torgler, 2021. "Artificial Intelligence and Big Data in Sustainable Entrepreneurship," CREMA Working Paper Series 2021-11, Center for Research in Economics, Management and the Arts (CREMA).
    10. Fumio Teramae & Tomohiro Makino & Yeongjoo Lim & Shintaro Sengoku & Kota Kodama, 2020. "Impact of Research and Development Strategy on Sustainable Growth in Multinational Pharmaceutical Companies," Sustainability, MDPI, vol. 12(13), pages 1-15, July.
    11. Fernando Antoñanzas & Robert Terkola & Maarten Postma, 2016. "The Value of Medicines: A Crucial but Vague Concept," PharmacoEconomics, Springer, vol. 34(12), pages 1227-1239, December.
    12. Csanádi, Marcell & Ozierański, Piotr & Löblová, Olga & King, Lawrence & Kaló, Zoltán & Botz, Lajos, 2019. "Shedding light on the HTA consultancy market: Insights from Poland," Health Policy, Elsevier, vol. 123(12), pages 1237-1243.
    13. Mills, Mackenzie & Kanavos, Panos, 2022. "How do HTA agencies perceive conditional approval of medicines? Evidence from England, Scotland, France and Canada," Health Policy, Elsevier, vol. 126(11), pages 1130-1143.
    14. Livio Garattini & Anna Padula, 2020. "HTA for pharmaceuticals in Europe: will the mountain deliver a mouse?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(1), pages 1-5, February.
    15. Sarri, Grammati & Freitag, Andreas & Szegvari, Boglarka & Mountian, Irina & Brixner, Diana & Bertelsen, Neil & Kaló, Zoltán & Upadhyaya, Sheela, 2021. "The Role of Patient Experience in the Value Assessment of Complex Technologies – Do HTA Bodies Need to Reconsider How Value is Assessed?," Health Policy, Elsevier, vol. 125(5), pages 593-601.
    16. Fontrier, Anna-Maria & Kamphuis, Bregtje W. & Kanavos, Panos, 2023. "How can health technology assessment be improved to optimise access to medicines? Results from a Delphi study in Europe," LSE Research Online Documents on Economics 120537, London School of Economics and Political Science, LSE Library.
    17. Fontrier, Anna-Maria, 2022. "Market access for medicines treating rare diseases: Association between specialised processes for orphan medicines and funding recommendations," Social Science & Medicine, Elsevier, vol. 306(C).
    18. Löblová, Olga & Csanádi, Marcell & Ozierański, Piotr & Kaló, Zoltán & King, Lawrence & McKee, Martin, 2019. "Alternative access schemes for pharmaceuticals in Europe: Towards an emerging typology," Health Policy, Elsevier, vol. 123(7), pages 630-634.
    19. Melanie Büssgen & Tom Stargardt, 2023. "Does health technology assessment compromise access to pharmaceuticals?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(3), pages 437-451, April.
    20. Anderson, Michael & Drummond, Michael & Taylor, David & McGuire, Alistair & Carter, Paul & Mossialos, Elias, 2022. "Promoting innovation while controlling cost: The UK's approach to health technology assessment," Health Policy, Elsevier, vol. 126(3), pages 224-233.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:19:y:2022:i:12:p:7281-:d:838392. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.